Novavax Is Finally Coming For BioNTech's Dominance

Oct. 28, 2021 5:56 PM ETBioNTech SE (BNTX), NVAX218 Comments


  • Comirnaty, the COVID-19 vaccine produced by Pfizer-BioNTech, has been recommended for children between 5 and 11 years old.
  • The White House has acquired sufficient vaccines from Pfizer-BioNTech. It is targeted for distribution to more than 25,000 pediatricians' offices, hospitals, and pharmacies.
  • On 27 October 2021, NVAX finally filed for authorization for its COVID-19 vaccine, NVX-CoV2373, in the UK.
  • NVAX is looking closer to fulfilling its "destiny," if it manages to finally obtain its emergency use authorization.
  • We discuss whether both stocks are a buy now for biotech investors.
  • I do much more than just articles at Ultimate Growth Investing: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »
Vials With the Covid-19 Vaccine and Syringes are Displayed On a Tray at the Corona Vaccination Center

Morsa Images/DigitalVision via Getty Images

Investment Thesis

Novavax (NASDAQ:NVAX) has finally filed for authorization for its COVID-19 vaccine, NVX-CoV2373, in the UK. NVX-CoV2373 is a two-dose protein subunit-based vaccine. It contains a proprietary Matrix-M adjuvant. In contrast to Pfizer-BioNTech, Novavax's vaccine uses the Recombinant Nanoparticle Vaccine Technology. It has also been proven to be 93% clinically effective. Novavax has filed for Emergency Use Listing (EUL) from the World Health Organization (WHO). The company also expects to file for Emergency Use Authorization (EUA) with the US FDA by Q4'21. Besides its COVID-19 vaccine, Novavax also has eight other programs in development. Three of the programs are in the Phase 2/3 clinical stage.

BioNTech SE (NASDAQ:BNTX) is one of the two key players behind the leading and highly successful COVID-19 vaccine, Comirnaty. It has delivered more than a billion doses worldwide as of 21 July 2021. On 27 October 2021, the vaccine was also recommended for children between 5 and 11 years old. In addition, BNTX has also rapidly expanded the scope of its R&D efforts to sustain its success beyond Comirnaty by deploying some of that cash to build up its capabilities in "Next-Gen Immunotherapies & Vaccines." More than 20 potential candidates are in the pipeline with a target to launch "multiple products in the next five years."

If you are new to Novavax and BioNTech, we encourage you to read our recent articles on both companies. They will help you understand their business models and market opportunity better. The links to the articles are appended:

NVAX Vs. BNTX Stock YTD Performance

NVAX Vs. BNTX stock YTD performance (as of 27 October 21).

BNTX stock has had a phenomenal year so far. At one point in August, its YTD gain almost reached 400%. Although the momentum has subsided substantially, its YTD gain of 249% should still be gratifying for its investors. In contrast, NVAX stock has had a topsy-turvy year. Its YTD gain raced to more than 150% earlier this year. However, its momentum has all but fizzled out. Its YTD gain has fallen dramatically to 29.6%. Its struggle for traction this year also mirrored its struggles in obtaining its EUA for its COVID-19 vaccine.

Comirnaty Continues to Lead the Race in Protecting Children

On 27 October 2021, Comirnaty, the COVID-19 vaccine produced by Pfizer-BioNTech, has been recommended for children between 5 and 11 years old. It is based on the voting results from a panel of FDA advisors. The vote is 17-0 in favor of the vaccine. The advisors believe that the benefits of the COVID-19 vaccine outweigh the risks of heart inflammation. As a result, we may expect a formal FDA approval within this week. It is after the discussion by CDC's Advisory Committee on Immunization Practices on 2nd November 2021. The White House has also acquired sufficient specially packaged children vaccines from Pfizer-BioNTech. The vaccines are ready for distribution to more than 25,000 pediatrician's offices, hospitals, and pharmacies.

It is indeed excellent news for the medical community. It will help to reduce the mortality rate for children with underlying medical conditions. As of 26 October 2021, 737K deaths have been reported in the US. Of these, the American Academy of Pediatrics estimated that children accounted for up to 0.26% of all COVID-19 deaths. As of May 2021, UNICEF estimated 3.48K of children aged 9 and below to have died globally from COVID-19.

The number of Child COVID-19 Cases Added weekly. Source: American Academy of Pediatrics.

Furthermore, most of these unvaccinated children have returned to school in Q2'21. The American Academy of Pediatrics reported that more and more children in the US have tested positive for COVID-19 recently. Almost 1.89M US children fell sick in the recent 2.5 months. Assuming a rollout of vaccines by November 2021, 28M young Americans can finally be better protected from COVID-19.

It will save lives in that age group,” says Emma McBryde, an infectious-diseases modeller at the Australian Institute of Tropical Health and Medicine in Townsville. “For every child’s life you save, you may well save many, many more adult lives,” she says. This is because the infected children may transit the COVID-19 to others, including adults. (from nature article)

The kid effect: A simulation of the effect of vaccinating US children aged 5 to 11 against COVID-19 in early November 2021.

Vaccines for children aged 5–11 could reduce new US infections and deaths. Source: COVID-19 Scenario Modeling Hub

Vaccinating the children may help to reduce the impact from potential future variants based on the study above. Hence, it serves not just to protect our children, but also confer a significant benefit to society.

NVAX is Finding Its Cadence

On 27 October 2021, NVAX finally filed for authorization for its COVID-19 vaccine, NVX-CoV2373, in the UK. NVAX is the first company to submit for Conditional Marketing Authorization (CMA) of a protein-based COVID-19 vaccine in the UK. The company had submitted complete data to the regulator. It includes preclinical, clinical, and chemistry, manufacturing, and controls (CMC) data. CEO Stanley C. Erck added:

We look forward to U.K. Medicines and Healthcare products Regulatory Agency's (MHRA) review and will be prepared to deliver vaccine doses following what we anticipate will be a positive decision. (from Novavax news report)

NVAX is confident that the complete submission to the US FDA will be made by the end of 2021. NVAX also expects to submit authorization in Europe, Canada, Australia, and New Zealand. It is on top of a pending approval for Emergency Use Listing (EUL) from World Health Organization (WHO), Indonesia, and the Philippines. Serum Institute of India's (SII) CEO also reported that NVX-CoV2373 should be licensed in India by the end of 2021 or early 2022. In addition, it was reported that the vaccine's complete data would be submitted to the regulatory board soon. Thus, it seems that NVAX is finally finding its cadence for regulatory submissions. As a result, NVAX is leaning closer to its potential EUA approval by the US FDA.

NVAX has also closed multiple Advance Purchase Agreements (APA), amounting to 450M total doses despite the lack of regulatory approval. These doses are meant for the US, Japan, and Europe. It demonstrates confidence shown by the international community. NVAX has also pledged over 1B doses for the developing world, with Serum Institute of India producing 600M annually.

In Q2'21, NVAX reported deferred revenue of $1.2B. It comprised $1.1B from upfront payments under the APAs. NVAX expects to fulfill these unsatisfied performance obligations by 2022. In addition, the company highlighted that it has unfulfilled performance obligations amounting to $7B. Therefore, we think the opportunity to realize its unfulfilled purchase obligations in 2022 is getting closer than before. Novavax also expects to have a production capacity of 2B doses by 2022.

So, Which Stock is the Better Buy Now?

BioNTech & Novavax stock EV/Fwd Revenue trend. Source: S&P Capital IQ

NVAX is currently trading at an EV/NTM Revenue of 2.39x, while BNTX is trading at 3.35x. However, if we consider the fulfillment of its $7B worth of purchase obligations by 2022, its stock is trading at just 1.6x of its FY22 estimated revenue. As compared to BNTX stock, NVAX stock certainly looks like a huge bargain now.

Notwithstanding, many investors may still be cautious about NVAX stock due to multiple delays on its EUA submissions and manufacturing issues. However, as the company inches closer to a potential rollout if it obtains its EUA, its valuation looks attractive now. Nevertheless, we think NVAX stock should still be considered as a speculative play for investors.

In contrast, BNTX already has a proven vaccine with Pfizer. Thus, even though BNTX stock trades at a significant premium over NVAX stock, it might seem to be the smarter buy for some investors. Moreover, both stocks don't look expensive now, ever since their recent valuation compression.

Therefore, we rate both stocks at Buy. However, if you have the appetite for speculation, NVAX stock might prove to be the outperformer at its current valuation.

Do you want to buy only at the right entry points for your growth stocks?

We help you to pick lower-risk entry points, ensuring you are able to capitalize on them with a higher probability of success and profit on their next wave up. Your membership also includes:

  • 24/7 access to our model portfolios

  • Daily Tactical Market Analysis to sharpen your market awareness and avoid the emotional rollercoaster

  • Access to all our top stocks and earnings ideas

  • Access to all our charts with specific entry points

  • Real-time chatroom support

  • Real-time buy/sell/hedge alerts

Sign up now for a Risk-Free 14-Day free trial!

This article was written by

JR Research profile picture
Sifting through the ultimate growth stocks for your portfolio

I'm JR, the lead writer and founder of JR Research and Ultimate Growth Investing Marketplace service. Our team is committed to bringing more clarity to investors in their investment decisions.

Our marketplace service focuses on a price-action-based approach to growth and technology stocks, supported by fundamental analysis. In addition, our general SA site discusses stocks from various sectors and industries. 

Our discussion mainly focuses on a short- to medium-term thesis. While we hold stocks for the long-term, we also use appropriate opportunities to benefit from short- to medium-term swings, leveraging long (directionally bullish) or short (directionally bearish) set-ups. 

My LinkedIn:

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (218)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.